Making engineered immune cells tougher so they can fight solid tumors
Synthetic metabolism to armor and enhance a new class of cell therapies
['FUNDING_OTHER'] · GEORGIA INSTITUTE OF TECHNOLOGY · NIH-11238576
This project aims to give engineered T cell therapies new metabolic tools so they can survive and kill cancer cells in the harsh tumor environment.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGIA INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11238576 on ClinicalTrials.gov |
What this research studies
Researchers plan to reprogram CAR T cells with synthetic metabolic pathways so the cells can better compete for nutrients, break down harmful metabolic byproducts, and turn on protective genes when inside tumors. The team will use metabolic engineering and synthetic biology to build these functions into T cells and test them in laboratory and preclinical models. Work will focus on overcoming the nutrient-depletion and toxic-byproduct barriers that commonly stop T cells from working in solid cancers. If these lab advances succeed, they could form the basis for future clinical trials of improved cell therapies for patients with solid tumors.
Who could benefit from this research
Good fit: People with solid tumors who might be candidates for autologous CAR T–type cell therapy in future clinical trials would be the ideal participants.
Not a fit: Patients without cancer, those with cancers already well controlled by existing treatments, or people not eligible for cell therapy would likely not benefit from this specific work.
Why it matters
Potential benefit: If successful, this could make cell therapies more effective against solid tumors by helping immune cells survive and function inside cancers.
How similar studies have performed: CAR T therapies have shown clear success in some blood cancers, but applying metabolic engineering to help CAR T cells work in solid tumors is a newer and largely untested approach in humans.
Where this research is happening
ATLANTA, UNITED STATES
- GEORGIA INSTITUTE OF TECHNOLOGY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BLAZECK, JOHN JAMES — GEORGIA INSTITUTE OF TECHNOLOGY
- Study coordinator: BLAZECK, JOHN JAMES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers